Tharimmune's TH104 to Be Presented at Notable Medical Conferences

Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biopharmaceutical company, announced that abstracts on its leading drug candidate, TH104, will be presented at upcoming medical conferences. These include the Digestive Disease Week (DDW) Annual Meeting in San Diego and the European Association for the Study of the Liver (EASL) International Liver Congress in Amsterdam, both scheduled for May 2025.

The abstracts will present new clinical data and insights on TH104's potential to address unmet needs in immunological and inflammatory disorders. At DDW, TH104's pharmacokinetics in healthy subjects will be highlighted, while the EASL congress will feature the drug's metabolism for treating pruritus in primary biliary cholangitis.